This article is more than 5 years old. Information may no longer be current.

FDA approves AcrySof IQ ReSTOR +2.5 D IOL for cataract patients

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alcon received FDA approval for the AcrySof IQ ReSTOR +2.5 D IOL, according to a Novartis press release.

The multifocal lens is approved for patients who are undergoing cataract surgery and seek correction of near, intermediate and distance vision at the same time, the release said.

The IOL will be eligible for reimbursement as both a Medicare-covered service for the treatment of cataract and a non-covered service for the correction of presbyopia, the release said.

The AcrySof IQ ReSTOR +2.5 D IOL is commercially available in the European Union, Australia, Canada, Japan, and countries in Central and South America. It will be commercialized in the U.S. in the near future, the release said.